Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy trial shows promise for shrinking advanced colon tumors

NCT ID NCT02060188

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This completed Phase 2 trial tested whether the immunotherapy drug nivolumab, either alone or combined with other cancer drugs, could meaningfully shrink tumors in people with advanced colon cancer that had returned or spread. The study enrolled 385 participants whose tumors had specific genetic markers. Researchers measured how many patients experienced significant tumor reduction as their primary goal.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MICROSATELLITE STABLE COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Local Institution - 0001

    San Francisco, California, 94115, United States

  • Local Institution - 0002

    Boston, Massachusetts, 02114, United States

  • Local Institution - 0003

    Houston, Texas, 77030-4009, United States

  • Local Institution - 0004

    Los Angeles, California, 90033, United States

  • Local Institution - 0005

    Portland, Oregon, 97213, United States

  • Local Institution - 0006

    Nashville, Tennessee, 37232, United States

  • Local Institution - 0008

    Atlanta, Georgia, 30322, United States

  • Local Institution - 0010

    Madrid, 28050, Spain

  • Local Institution - 0011

    Seville, 41013, Spain

  • Local Institution - 0012

    Madrid, Madrid, 28009, Spain

  • Local Institution - 0013

    Pittsburgh, Pennsylvania, 15232, United States

  • Local Institution - 0016

    Toronto, Ontario, M5G 1X5, Canada

  • Local Institution - 0018

    Brussels, 1090, Belgium

  • Local Institution - 0019

    Brussels, 1000, Belgium

  • Local Institution - 0020

    Leuven, 3000, Belgium

  • Local Institution - 0022

    Dublin, 0, Ireland

  • Local Institution - 0023

    Dublin, 0, Ireland

  • Local Institution - 0024

    Durham, North Carolina, 27710, United States

  • Local Institution - 0025

    Paris, 75571, France

  • Local Institution - 0027

    Edmonton, Alberta, T6G 1Z2, Canada

  • Local Institution - 0028

    Gilbert, Arizona, 85234, United States

  • Local Institution - 0029

    Winston-Salem, North Carolina, 27103, United States

  • Local Institution - 0030

    Candiolo, Torino, 10060, Italy

  • Local Institution - 0032

    Padua, Padova, Italy

  • Local Institution - 0033

    Galway, 0, Ireland

  • Local Institution - 0034

    Minneapolis, Minnesota, 55407, United States

  • Local Institution - 0035

    Modena, 41124, Italy

  • Local Institution - 0036

    Boston, Massachusetts, 02114, United States

  • Local Institution - 0037

    Melbourne, Victoria, 3000, Australia

  • Local Institution - 0039

    Southport, Queensland, 4215, Australia

  • Local Institution - 0040

    Westmead, New South Wales, 2145, Australia

  • Local Institution - 0041

    Allentown, Pennsylvania, 18103, United States

Conditions

Explore the condition pages connected to this study.

MICROSATELLITE STABLE COLORECTAL CANCER MICROSATELLITE UNSTABLE COLORECTAL CANCER MISMATCH REPAIR DEFICIENT COLORECTAL CANCER MISMATCH REPAIR PROFICIENT COLORECTAL CANCER